Oruka Therapeutics, Inc. (NASDAQ: ORKA) is emerging as a noteworthy player in the biotechnology sector, captivating investors with its focus on innovative monoclonal antibody therapeutics aimed at tackling psoriasis and other inflammatory conditions. Headquartered in Menlo Park, California, the company stands at the forefront of biopharmaceutical advancements, primarily targeting the interleukin pathways with its robust pipeline of clinical-stage products.

**Market Position and Stock Performance**

With a market capitalization of $1.58 billion, Oruka Therapeutics is a significant entity in the healthcare industry. Currently trading at $32.64, the stock has experienced a remarkable journey, with its 52-week range stretching from…